Jane Street’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21M | Buy |
279,800
+210,200
| +302% | +$16.6M | ﹤0.01% | 1747 |
|
|
2025
Q4 | $5.51M | Buy |
69,600
+1,100
| +2% | +$82.8K | ﹤0.01% | 3080 |
|
|
2025
Q3 | $4.48M | Buy |
68,500
+10,300
| +18% | +$503K | ﹤0.01% | 3590 |
|
|
2025
Q2 | $2.3M | Sell |
58,200
-1,500
| -3% | -$49.1K | ﹤0.01% | 4202 |
|
|
2025
Q1 | $1.8M | Sell |
59,700
-600
| -1% | -$19.6K | ﹤0.01% | 4534 |
|
|
2024
Q4 | $2.11M | Buy |
60,300
+54,400
| +922% | +$2.03M | ﹤0.01% | 4019 |
|
|
2024
Q3 | $236K | Sell |
5,900
-20,100
| -77% | -$935K | ﹤0.01% | 8403 |
|
|
2024
Q2 | $1.24M | Sell |
26,000
-1,000
| -4% | -$41K | ﹤0.01% | 5366 |
|
|
2024
Q1 | $1.17M | Sell |
27,000
-46,500
| -63% | -$2.22M | ﹤0.01% | 5114 |
|
|
2023
Q4 | $3.72M | Buy |
73,500
+17,700
| +32% | +$848K | ﹤0.01% | 3299 |
|
|
2023
Q3 | $2.53M | Sell |
55,800
-58,400
| -51% | -$2.41M | ﹤0.01% | 3648 |
|
|
2023
Q2 | $4.69M | Buy |
114,200
+85,000
| +291% | +$3.27M | ﹤0.01% | 2841 |
|
|
2023
Q1 | $1.04M | Sell |
29,200
-5,800
| -17% | -$218K | ﹤0.01% | 4916 |
|
|
2022
Q4 | $1.32M | Sell |
35,000
-28,100
| -45% | -$1.18M | ﹤0.01% | 4528 |
|
|
2022
Q3 | $2.79M | Buy |
63,100
+37,700
| +148% | +$1.59M | ﹤0.01% | 3580 |
|
|
2022
Q2 | $940K | Sell |
25,400
-4,600
| -15% | -$173K | ﹤0.01% | 5585 |
|
|
2022
Q1 | $1.11M | Sell |
30,000
-10,800
| -26% | -$354K | ﹤0.01% | 5915 |
|
|
2021
Q4 | $1.24M | Buy |
40,800
+8,600
| +27% | +$271K | ﹤0.01% | 5464 |
|
|
2021
Q3 | $1.08M | Sell |
32,200
-10,600
| -25% | -$399K | ﹤0.01% | 5758 |
|
|
2021
Q2 | $1.71M | Sell |
42,800
-11,600
| -21% | -$454K | ﹤0.01% | 4655 |
|
|
2021
Q1 | $2.45M | Buy |
54,400
+4,600
| +9% | +$257K | ﹤0.01% | 3647 |
|
|
2020
Q4 | $2.82M | Buy |
49,800
+16,600
| +50% | +$827K | ﹤0.01% | 2905 |
|
|
2020
Q3 | $1.57M | Sell |
33,200
-22,100
| -40% | -$1.23M | ﹤0.01% | 3388 |
|
|
2020
Q2 | $3.26M | Buy |
55,300
+24,900
| +82% | +$1.39M | ﹤0.01% | 2390 |
|
|
2020
Q1 | $1.44M | Buy |
+30,400
| New | +$1.69M | ﹤0.01% | 2370 |
|
|
2018
Q4 | – | Sell |
-5,100
| Closed | -$263K | – | 5311 |
|
|
2018
Q3 | $263K | Buy |
+5,100
| New | +$240K | ﹤0.01% | 4378 |
|
|
2018
Q1 | – | Sell |
-10,400
| Closed | -$523K | – | 5082 |
|
|
2017
Q4 | $523K | Buy |
+10,400
| New | +$570K | ﹤0.01% | 3119 |
|
|
2017
Q1 | – | Sell |
-7,900
| Closed | -$378K | – | 4404 |
|
|
2016
Q4 | $378K | Buy |
+7,900
| New | +$313K | ﹤0.01% | 3129 |
|
|
2016
Q2 | – | Sell |
-10,500
| Closed | -$425K | – | 4313 |
|
|
2016
Q1 | $425K | Sell |
10,500
-1,000
| -9% | -$40.6K | ﹤0.01% | 2785 |
|
|
2015
Q4 | $712K | Buy |
+11,500
| New | +$621K | ﹤0.01% | 2104 |
|
|
2015
Q3 | – | Sell |
-4,200
| Closed | -$242K | – | 3855 |
|
|
2015
Q2 | $242K | Sell |
4,200
-8,000
| -66% | -$509K | ﹤0.01% | 3066 |
|
|
2015
Q1 | $777K | Buy |
+12,200
| New | +$828K | 0.01% | 1598 |
|
Other funds holding IONS
VPM
VCM
Jane Street's IONS Position: Q1 2026 in Review
Jane Street increased its Ionis Pharmaceuticals (IONS) stake by 530% in Q1 2026, buying an estimated $12.7M and bringing the position to 191,818 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2111.
Jane Street first reported a position in IONS in Q2 2013 and has held it in 47 quarters since. The position peaked at $23.9M in Q3 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Jane Street held 191,818 shares of Ionis Pharmaceuticals worth $14.4M as of Q1 2026.
- Jane Street bought 161,347 Ionis Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
- Ionis Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2111 holding.
- Jane Street first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Jane Street's Ionis Pharmaceuticals position peaked at $23.9M in Q3 2025.
- 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.